To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
Sponsor: Hoffmann-La Roche
ClinicalTrials ID:NCT07368998
This study assesses the efficacy and safety of inavolisib with fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative LA/mBC post-CDKi. Eligible participants must have ER+/HER2- tumors, progressed post-CDK4/6i therapy, measurable disease, and a life expectancy over 6 months. Interventions include inavolisib and fulvestrant per protocol schedule.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with fulvestrant in participants with PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer (LA/mBC) in the post-cyclin-dependent kinase inhibitor (CDKi) setting.
Eligibility Criteria
Inclusion Criteria
- Documented ER +/ HER2- tumor according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines
- Disease progression after or during treatment with a combination of CDK4/6i and endocrine therapy: <= 1 prior lines of systemic therapy in the locally advanced (recurrent or progressed) or metastatic setting
- Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
- Participants for whom endocrine-based therapy is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study, as per national or local treatment guidelines
- Confirmation of biomarker eligibility: presence of >= 1 study-eligible PIK3CA mutation
- Life expectancy of > 6 months
- Ability, in the investigator's judgment, and willingness to comply with all study -related procedures, including completion of patient-reported outcomes
Exclusion Criteria
- Metaplastic breast cancer
- Prior treatment with chemotherapy in the recurrent locally advanced/metastatic setting
- Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes
- Prior treatment with PI3K/Akt/mTOR inhibitors in the recurrent locally advanced/metastatic setting
- Requirement for daily supplemental oxygen
- Symptomatic active lung disease, including pneumonitis
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Los Angeles Cancer Network | 90017-4803 | Los Angeles | California |
| Astera Cancer Care East Brunswick | 08816 | East Brunswick | New Jersey |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.